Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: A double blind randomized placebo controlled pilot clinical study

Nutrition Journal

Volumn 15, Issue 1, 2016, Pages

  Majeed, Muhammed ^a,b   Nagabhushanam, Kalyanam ^b   Natarajan, Sankaran ^a   Sivakumar, Arumugam ^a   Ali, Furqan ^a   Pande, Anurag ^b   Majeed, Shaheen ^c   Karri, Suresh Kumar ^d  

^a Sami Labs Limited   (India)

^b SABINSA CORPORATION   (United States)

^c SABINSA CORPORATION   (United States)

^d ClinWorld Private Limited   (India)

Author keywords

Bacillus coagulans; Diarrhea; Irritable Bowel Syndrome; Lactobacillus; LactoSpore

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ABDOMINAL PAIN; ADULT; ARTICLE; BACILLUS COAGULANS; BLOATING; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IRRITABLE COLON; MALE; MULTICENTER STUDY; NONHUMAN; PILOT STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; VISUAL ANALOG SCALE; ADOLESCENT; BACILLUS; CLINICAL TRIAL; DISEASE MANAGEMENT; GASTROINTESTINAL TRACT; INTESTINE FLORA; IRRITABLE BOWEL SYNDROME; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PAIN MEASUREMENT; QUESTIONNAIRE; TREATMENT OUTCOME; YOUNG ADULT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; BACILLUS; DIARRHEA; DISEASE MANAGEMENT; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PAIN MEASUREMENT; PILOT PROJECTS; PROBIOTICS; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84959363387     PISSN: None     EISSN: 14752891     Source Type: Journal    
DOI: 10.1186/s12937-016-0140-6     Document Type: Article

References (37)

1. FAO/WHO. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria, Report of a Joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live Lactic acid bacteria. Córdoba, Argentina: 2001. Available at: ftp://ftp.fao.org/docrep/fao/009/a0512e/a0512e00.pdf. Accessed 24 February 2016.AQ7
2. Gill H, Prasad J. Bioactive components of milk: probiotics, immunomodulation, and health benefits. In: Bosze Z, editor. Advances in experimental medicine and biology. New York: Springer; 2008. p. 423-64.
3. Britton RA, Versalovic J. Probiotics and gastrointestinal infections. Interdiscip Perspect Infect Dis. 2009;2008:1-10.
4. Vaclav V, Jana V. Physiological effects of a combination of cinnulin with probiotics. Am J Immunol. 2013;9:103-9.
5. Figueroa-González I, Quijano G, Ramírez G, Cruz-Guerrero A. Probiotics and prebiotics - perspectives and challenges. J Sci Food Agric. 2011;91:1341-8.
6. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91.
7. Luyer MD, Buurman WA, Hadfoune M, Speelmans G, Knol J, Jacobs JA, Dejong CH, Vriesema AJ, Greve JW. Strain-specific effects of probiotics on gut barrier integrity following hemorrhagic shock. Infect Immun. 2005;73(6):3686-92.
8. Kekkonen RA, Lummela N, Karjalainen H, Latvala S, Tynkkynen S, Jarvenpaa S, Kautiainen H, Julkunen I, Vapaatalo H, Korpela R. Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults. World J Gastroenterol. 2008;14(13):2029-36.
9. Lee IC, Tomita S, Kleerebezem M, Bron PA. The quest for probiotic effector molecules - unraveling strain specificity at the molecular level. Pharmacol Res. 2013;69(1):61-74.
10. Million M, Raoult D. Species and strain specificity of Lactobacillus probiotics effect on weight regulation. Microb Pathog. 2013;55:52-4.
11. Majeed M, Prakash L. LactoSpore® - Lactic acid bacillus -Lactobacillus Sporogenes. Piscataway: Nutri science publishers; 2008.
12. Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Eshuis-de Ruiter T, Booij-Veurink J, de Vries YP, Ali F. Evaluation of genetic and phenotypic consistency of Bacillus coagulans MTCC 5856: a commercial probiotic strain. World J Microbiol Biotechnol. Doi: 10.1007/s11274-016-2027-2.
13. Majeed M, Majeed S, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F. Evaluation of the stability of Bacillus coagulans MTCC 5856 during processing and storage of functional foods. Int J Food Sci Technol. 2016. doi: 10.1111/ijfs.13044.
14. Anonymous. 52nd WMA General Assembly, Edinburgh, Scotland; 2000.
15. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377-90.
16. Bovenschen HJ, Janssen MJR, van Oijen MGJ, Laheij RJF, van Rossum LGM, Jansen JBMJ. Evaluation of a gastrointestinal symptoms questionnaire. New York: Springer Science + Business Media, Inc; 2006.
17. Camilleri M, Chang L. Challenges to the therapeutic pipeline for irritable bowel syndrome: End points and regulatory hurdles. Gastroenterology. 2008;135:1877-91.
18. Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Breivik Hals EK, Kvarstein G, Stubhaug A. Assessment of pain. BJA. 2008;101(1):17-24.
19. Spencer DD, Carolyn DM, Susan ES, Schneck TM, Hopper YBH, Renuka K, Stephan RW, William FM, Nancy JN, Douglas AD. Development and validation of the irritable bowel syndrome satisfaction with care scale. Clin Gastroenterol Hepatol. 2011;9:1065-71.
20. Borgaonkar MR, Irvine EJ. Quality of life measurement in gastrointestinal and liver disorders. Gut. 2000;47:444-54.
21. King CK, Glass R, Bresee JS, Duggan C. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep. 2003;52(RR-16):1-16.
22. Tuohy KM, Probert HM, Smejkal CW, Gibson GR. Using probiotics and prebiotics to improve gut health. Drug Discov Today. 2003;8(15):692-700.
23. FAO/WHO. Working Group. Guidelines for the evaluation of probiotics in food. Report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food. London, Ontario, Canada, April 30 and May 1, 2002. Available at: ftp://ftp.fao.org/es/esn/food/wgreport2.pdf. Accessed 24 February 2016.
24. Gill H, Prasad J. Probiotics, immunomodulation, and health benefits. Adv Exp Med Biol. 2008;606:423-54.
25. Shida K, Nomoto K. Probiotics as efficient immunopotentiators: translational role in cancer 1 prevention. Indian J Med Res. 2013;138:808-14.
26. Brenner D, Moeller M, Chey W, Schoenfeld P. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104:1033-49.
27. Mazloom Z, Yousefinejad A, Dabbaghmanesh MH. Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: a clinical trial. IJMS. 2013;38(1):38-43.
28. Takeshi M, Ryuta Y, Shusuke H, Teruo Y. Antidiabetic effects of an oral administration of lactobacillus casei in anon-insulin-dependent diabetes mellitus (NIDDM) model using KK-AY mice. Endocr J. 1997;44(3):357-65.
29. Yun SI, Park HO, Kang JH. Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. J Appl Microbiol. 2009;107:1681-6.
30. Hsieh FC, Lee CL, Chai CY, Chen WT, Lu YC, Wu CS. Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rat. Nutr Metab. 2013;10(35):1-14.
31. Collins SM. A case for an immunological basis for irritable bowel syndrome. Gastroenterology. 2002;122:2078-80.
32. Majeed M, Majeed S, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Anurag P, Suresh KK. Evaluation of anti-diarrhoeal activity of bacillus coagulans mtcc 5856 and its effect on gastrointestinal motility in wistar rats. IJPBS. 2016;7(1):311-16.
33. Anonymous. ICH Topic E 10. Choice of control group and related issues in clinical trials. ICH guidance document. 2000; 4: p. 1-29.
34. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541-51.
35. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 2007;26:475-86.
36. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein A. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut. 2008;59(3):325-32.
37. Majeed M, Nagabhushanam K, Arumugam S, Furqan Ali. Process for enhancing the viable counts of Lactic Acid Bacteria and useful compositions thereof. 2015. US application No. 14839923 and PCT/US2015/47608.